Vermillion Plans to Raise Up to $17.3M in Stock Offering

The company said it will use the funds to expand into international markets, fund clinical trials for its peripheral artery disease test, "pursue opportunities to diversity our product and service lines and offerings," and for general corporate purposes.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.